SCHEMBL22893592

SCHEMBL22893592

CC(C(=O)OCc1ccccc1)C1(O)CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.49
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
MAPT P10636 3/20 0.48
ALOX15 P16050 1/20 0.47
TACR1 P25103 1/20 0.47
OPRD1 P41143 1/20 0.47
OPRK1 P41145 1/20 0.47
GPR119 Q8TDV5 2/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
ATM Q13315 1/20 0.45
YAP1 P46937 1/20 0.45
STS P08842 1/20 0.44
NPSR1 Q6W5P4 3/20 0.44
MAPK1 P28482 2/20 0.44
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
NTSR1 P30989 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20487598 1.00 TSHR (0.49) TSHRMEN1KMT2AMAPTALOX15
SCHEMBL31397027 0.91 MEN1 (0.49) TSHRMEN1KMT2AMAPTALOX15
SCHEMBL23460540 0.88 OPRD1 (0.48) TSHRMEN1KMT2AMAPTALOX15
SCHEMBL3498595 0.82 TACR1 (0.49) TSHRMEN1KMT2AALOX15TACR1
SCHEMBL30121349 0.82 MEN1 (0.54) MEN1KMT2ATACR1OPRD1OPRK1
SCHEMBL13130080 0.81 TACR1 (0.50) TSHRMEN1KMT2AALOX15TACR1
SCHEMBL31566574 0.81 CCR1 (0.48) TSHRMEN1KMT2AMAPTALOX15
SCHEMBL22893595 0.81 GPR119 (0.46) TSHRALOX15TACR1OPRD1OPRK1
SCHEMBL20487576 0.81 GPR119 (0.46) TSHRALOX15TACR1OPRD1OPRK1
SCHEMBL3492937 0.81 MEN1 (0.51) TSHRMEN1KMT2AALOX15TACR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12145935-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2024-11-19 US disclosed
US-20240116929-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC, INC. 2024-04-11 US disclosed
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-10-24 US disclosed
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2023-10-24 US disclosed
US-20210284640-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Lazuli, Inc. 2021-09-16 US disclosed
US-11046685-B2 Inhibitors of (α-v)(β-6) integrin MORPHIC THERAPEUTIC, INC. (US) 2021-06-29 US disclosed
EP-3760202-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN Morphic Therapeutic, Inc. (US) 2021-01-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11046685-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV TSHR 2000/4885MEN1 3362/4885KMT2A 4013/4885
US-20210284640-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV TSHR 2021/4885MEN1 2836/4885KMT2A 3835/4885
US-12145935-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV TSHR 1938/4885MEN1 3127/4885KMT2A 3937/4885
US-11795167-B2 Inhibitors of (α-v)(β-6) integrin ITGB6, ITGA6, ITGAV TSHR 1938/4885MEN1 3127/4885KMT2A 3937/4885
US-20240116929-A1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN ITGB6, ITGA6, ITGAV TSHR 2021/4885MEN1 2836/4885KMT2A 3835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.